



(43) International Publication Date
15 January 2015 (15.01.2015)

(10) International Publication Number
WO 2015/006219 A1

(51) International Patent Classification:

A61K 9/20 (2006.01) A61K 9/28 (2006.01)
A61K 9/24 (2006.01)

(21) International Application Number:

PCT/US2014/045581

(22) International Filing Date:

7 July 2014 (07.07.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/843,799 8 July 2013 (08.07.2013) US

(71) Applicant: ABBVIE, INC. [US/US]; 1 North Waukegan Rd., AP06A - V0377, Chicago, Illinois 60064 (US).

(72) Inventors: HUANG, Ye; 33873 N. Summerfields Dr., Gurnee, Illinois 60031 (US). KOSKI, Andrew, K.; 1325 Chatsworth Ln., Hoffmann Estates, Illinois 60169 (US). PETERSON, Katherine, E.; 2577 N. Augusta Dr., Wadsworth, Illinois 60083 (US).

(74) Agents: GETTEL, Nancy, J. et al.; AbbVie, Inc., 1 North Waukegan Rd., AP06A - V0377, Chicago, Illinois 60064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: STABILIZED PHARMACEUTICAL DOSAGE FORMS COMPRISING ATRASENTAN

(57) Abstract: The present disclosure relates to: (a) stabilized pharmaceutical dosage forms comprising atrasenstan, or a pharmaceutically acceptable salt thereof, and, optionally, another therapeutic agent; (b) methods of using such pharmaceutical dosage forms to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising such pharmaceutical dosage forms and, optionally, a second pharmaceutical dosage form comprising another therapeutic agent; (d) methods for the preparation of such pharmaceutical dosage forms; and (e) pharmaceutical dosage forms prepared by such methods.



WO 2015/006219 A1